SEC Filings

AVEXIS, INC. filed this Form 8-K on 11/02/2017
Entire Document


Item 8.01.                                        Other Events.


On November 1, 2017, AveXis, Inc. (the “Registrant”) issued a press release to report data as of August 7, 2017 from the Registrant’s Phase 1 clinical trial of AVXS-101 in spinal muscular atrophy Type 1. These data were published in the New England Journal of Medicine in a paper titled “Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 9.01.                                        Financial Statements and Exhibits.


(d) Exhibits







Exhibit Description



Press Release, dated November 1, 2017, titled “AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Therapy in Spinal Muscular Atrophy Type 1.”



© AveXis, Inc. All Rights Reserved.